Characteristics and outcomes of COVID-19 patients admitted to a regional health system in the southeast
Texeira et al.,
Characteristics and outcomes of COVID-19 patients admitted to a regional health system in the southeast,
Open Forum Infectious Diseases, doi:10.1093/ofid/ofaa439.560
Retrospective 161 hospitalized patients in the USA showing non-statistically significant unadjusted increased mortality with HCQ.
Confounding by indication is likely.
Time varying confounding is likely. HCQ became controversial and was suspended towards the end of the period studied, therefore HCQ use was likely more frequent toward the beginning of the study period, a time when overall treatment protocols were significantly worse.
This study is excluded in the after exclusion results of meta
analysis:
unadjusted results with no group details; no treatment details; substantial
confounding by time likely due to declining usage over the early stages of the pandemic when overall treatment protocols improved dramatically; substantial unadjusted
confounding by indication likely.
risk of death, 79.3% higher, RR 1.79, p = 0.10, treatment 17 of 65 (26.2%), control 14 of 96 (14.6%).
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Texeira et al., 31 Dec 2020, retrospective, USA, peer-reviewed, 6 authors.
Abstract: Conclusion: Our study suggests that PLWH do not have a worse prognosis than
their matched controls for the most significant comorbid conditions affecting outcome
in COVID-19 disease. Further studies with a larger sample size are urgently needed to
confirm this finding.
Disclosures: Jihad Slim, MD, Abbvie (Speaker’s Bureau)Gilead (Speaker’s
Bureau)Jansen (Speaker’s Bureau)Merck (Speaker’s Bureau)ViiV (Speaker’s
Bureau)
362. A Modified Early Warning Score Predicts Decompensation in COVID-19
Patients
Joanna S. Cavalier, MD1; Benjamin Goldstein, PhD2; Cara L. O’Brien, MD1;
Armando Bedoya, MD, MMCi1; 1Duke University School of Medicine, Durham,
North Carolina; 2Duke University, Durham, NC
Session: P-12. COVID-19 Complications, Co-infections, and Clinical Outcomes
363. Acute Kidney Injury and Renal Replacement Therapy in Hospitalized
COVID-19 Patients in the United States and Other Geographic Regions
Shannon NovosadShannon NovosadLeah Gilbert, MD, MSPH1; Ibironke W. Apata,
MD1; Rahsaan Overton, MPH1; Shikha Garg, MD, MPH1; Lindsey Kim, MD1;
Brendan R. Jackson, MD, MPH1; Priti Patel, MD, MPH1; 1Centers for Disease Control
and Prevention, Atlanta, Georgia
CDC COVID-19 Clinical Team and COVID-NET Investigators
Session: P-12. COVID-19 Complications, Co-infections, and Clinical Outcomes
Background: Acute kidney injury (AKI) is a complication that has been
described among severely ill patients with COVID-19 and may be more common in those with underlying chronic kidney disease (CKD). Some patients
with AKI require renal replacement therapy (RRT), including continuous RRT
(CRRT). During the COVID-19 pandemic, some US areas experienced CRRT
supply shortages. We sought to describe the percent of hospitalized COVID-19
patients who developed AKI or needed RRT to inform patient care and resource
planning.
Methods: We searched for studies in the literature and public health investigations that described CKD, AKI, and/or RRT in COVID-19 patients from January
2020 onward. Studies were excluded if no CKD, AKI, or RRT information was provided. We abstracted counts of hospitalized COVID-19 patients, including those
admitted to intensive care units (ICU) who developed AKI, underwent RRT, and/
or had CKD. Data were pooled across cohorts by geographic region with available
data (US, China, or United Kingdom [UK]). We compared proportions using Chisquare tests.
Results: A total of 311 studies were identified; 23 studies (US n=11; China n=11;
UK n=1) that described kidney disease and/or kidney-related outcomes in hospitalized COVID-19 patients were included. Underlying CKD prevalence was higher in
US cohorts (10.3%) compared with China (2.5%) or UK (1.5%) (p< 0.0001). AKI was
markedly higher among hospitalized (31.3% vs. 6.4%; p < 0 .001) and ICU patients
(55.4% vs. 18.2%; p< 0.0001) in the US compared to China. The percent of ICU
patients requiring RRT in the US (16.8%) was significantly different from that reported
in China (12.5%) and the UK (23.9%) (p< 0.0001). Limitations include differences in
CKD and RRT definitions across studies.
Conclusion: AKI is a frequent outcome among US COVID-19 patients,
affecting almost one third of hospitalized and more than half of ICU patients.
AKI was reported more frequently in the US than China. The percent of
ICU patients who received RRT was higher in the US and UK than in China.
Understanding the occurrence of kidney-related outcomes among patients with
COVID-19 including the impact of underlying CKD and regional..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit